RT Journal Article
SR Electronic
T1 Effect of specific non-pharmaceutical intervention policies on SARS-CoV-2 transmission in the counties of the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.29.20221036
DO 10.1101/2020.10.29.20221036
A1 Yang, Bingyi
A1 Huang, Angkana T.
A1 Garcia-Carreras, Bernardo
A1 Hart, William E.
A1 Staid, Andrea
A1 Hitchings, Matt D.T.
A1 Lee, Elizabeth C.
A1 Howe, Chanelle J.
A1 Grantz, Kyra H.
A1 Wesolowksi, Amy
A1 Lemaitre, Joseph Chadi
A1 Rattigan, Susan
A1 Moreno, Carlos
A1 Borgert, Brooke
A1 Dale, Celeste
A1 Quigley, Nicole
A1 Cummings, Andrew
A1 McLorg, Alizée
A1 LoMonaco, Kaelene
A1 Schlossberg, Sarah
A1 Barron-Kraus, Drew
A1 Shrock, Harrison
A1 ,
A1 Lessler, Justin
A1 Laird, Carl D.
A1 Cummings, Derek A.T.
YR 2020
UL http://medrxiv.org/content/early/2020/11/03/2020.10.29.20221036.abstract
AB Non-pharmaceutical interventions (NPIs) remain the only widely available tool for controlling the ongoing SARS-CoV-2 pandemic. We estimated weekly values of the effective basic reproductive number (Reff) using a mechanistic metapopulation model and associated these with county-level characteristics and NPIs in the United States (US). Interventions that included school and leisure activities closure and nursing home visiting bans were all associated with an Reff below 1 when combined with either stay at home orders (median Reff 0.97, 95% confidence interval (CI) 0.58-1.39)* or face masks (median Reff 0.97, 95% CI 0.58-1.39)*. While direct causal effects of interventions remain unclear, our results suggest that relaxation of some NPIs will need to be counterbalanced by continuation and/or implementation of others.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the Department of Health and Human Services (DATC, JL). Contributions from Sandia National Laboratories were partially funded by the Laboratory Directed Research and Development (LDRD) program, and the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research uses publicly available, deidentified data and does not constitute human subjects research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code for analysis are made available at https://github.com/datcummings/SARS-CoV-2.NPI.analysis. https://github.com/datcummings/SARS-CoV-2.NPI.analysis